Spironolactone
Product Images NDC 53808-0338

5 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 53808-0338). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

This Is The Label For Spironolactone Tablets 100 mg (Spironolactone 100mg(qualitest))

This Is The Label For Spironolactone Tablets 100 mg (Spironolactone 100mg(qualitest))
Label for Spironolactone 100 mg tablets, quantity of 30. The label includes RX only designation, lot number T180J09A, expiration date 063010, and package information by DOH Central Pharmacy, Tallahassee, FL 32304. A barcode and UPC number 306035765212 are also visible.*
FDA Label Image

This Is The Label For Spironolactone Tablets 25 mg (Spironolactone 25mg (qualitest))

This Is The Label For Spironolactone Tablets 25 mg (Spironolactone 25mg (qualitest))
Label for Spironolactone 25 mg tablets, prescription only, containing 30 tablets. The label includes lot number, expiration date, and is marked as packaged by DOH Central Pharmacy in Tallahassee, Florida. A barcode and UPC code are also visible.*
FDA Label Image

This Is An Image Of The Structural Formula For Spironolactone. (Spironolactonetabs 1)

This Is An Image Of The Structural Formula For Spironolactone. (Spironolactonetabs 1)
Chemical structure of spironolactone, showing its steroidal ring system with various functional groups including a lactone ring and thioester side chain. The molecular formula C24H32O4S and molecular weight 416.57 are visible.*
FDA Label Image

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)

This Is Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 2)
A Kaplan-Meier survival curve chart comparing the probability of an event over time in months between Spironolactone and placebo groups, with significant separation between the two lines and a log-rank p-value of less than 0.001 indicating statistical difference.*
FDA Label Image

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)

This Is An Image Of Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactonetabs 3)
A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups comparing spironolactone and placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use, with the number of participants (N) listed for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.